Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma

Gynecologic Oncology

Volumn 126, Issue 1, 2012, Pages 118-123

  Wender, Paul A ^a   Galliher, Wesley C ^a   Bhat, Neelima M ^b   Pillow, Thomas H ^a   Bieber, Marcia M ^b   Teng, Nelson N H ^b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; Human; Oligoarginine; Ovarian carcinoma; Taxol

Indexed keywords

ARGININE DERIVATIVE; PACLITAXEL; PACLITAXEL DERIVATIVE; PROPIDIUM IODIDE;

ARTICLE; ASCITES CELL; BLOOD; BYSTANDER EFFECT; CANCER PATIENT; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG RELEASE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEUKOCYTE; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SOLID TUMOR; TREATMENT OUTCOME; TUMOR CELL;

AGED; AGED, 80 AND OVER; ARGININE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PACLITAXEL; PRODRUGS;

EID: 84862768802     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.03.049     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Greenlee RT, Hill-HarmonMB,Murray T, ThunM. Cancer statistics, 2001. CA Cancer J Clin 2001;51:5-36.
3. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci U S A 2006;103:11154-9. (Pubitemid 44156488)
4. Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol 2002;87:77-83. (Pubitemid 36027105)
5. Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAMxanti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13:3899-905. (Pubitemid 47037597)
6. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol 2010;596:47-76.
7. Aller S, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009;323:1718-22.
8. Gatlik-Landwojtowicz E, Aanismaa P, Seelig A. Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry 2006;45:3020-32. (Pubitemid 43334550)
9. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem Feb 1998;251:252-61. (Pubitemid 28081437)
10. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34. (Pubitemid 43336035)
11. Dubikovskaya EA, Thorne SH, Pillow TH, Contag CH, Wender PA. Overcoming multi-drug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters. Proc Natl Acad Sci U S A 2008;105:12128-33.
12. Wender PA, Galliher WC, Goun EA, Jones LR, Pillow TH. The design of guanidinium-rich transporters and their internalization mechanisms. Adv Drug Deliv Rev 2008;60:452-72.
13. Fonseca SB, PereiraMP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 2009;61:953-64.
14. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7. (Pubitemid 9114288)
15. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7.
16. Straubinger RM. Biopharmaceutics of paclitaxel [Taxol]: formulation, activity, and pharmacokinetics. In: Suffness M, editor. Taxol science and applications. Boca Raton, FL: CRC Press; 1995. p. 237-58.
17. GelderblomH, Verweij J, Nooter K, SparreboomA. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8. (Pubitemid 32778603)
18. Armstrong DK, Bundy B,Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43. (Pubitemid 43048949)
19. Liu B, Wang T, Qian X, Liu G, Yu L, Ding Y. Anticancer effect of tetrandrine on primary cancer cells isolated from ascites and pleural fluids. Cancer Lett 2008;268:166-75.
20. Richard C, Matthews D, DuivenvoordenW, Yau J,Wright PS, Th'ng JPH. Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids. Clin Cancer Res 2005;11:3523-9. (Pubitemid 40627907)
21. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 1968;97:77-89.
22. Kingston DG. Recent advances in the chemistry of taxol. J Nat Prod 2000;63:726-34. (Pubitemid 30395547)
23. Ho CM, Huang YJ, Chen TC, Huang S-H, Liu F-S, Chang Chien C-C, et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 2004;94:197-203. (Pubitemid 38950520)
24. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol 1995;13:2961-7.
25. Frankel A, Buckman R, Kerbel RS. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 1997;57:2388-93. (Pubitemid 27255896)
26. Nicholson KM, BibbyMC, Phillips RM. Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. Eur J Cancer 1997;33:1291-8. (Pubitemid 27359651)
27. Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, et al. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 2000;77:258-63. (Pubitemid 30317146)
28. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23. (Pubitemid 44450469)
29. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A 2000;97:13003-8.
30. Saito G, Swanson JA, Lee K-D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 2003;55:199-215. (Pubitemid 36135916)
31. Obrador E, Navarro J, Mompo J, Asensi M, Pellicer JA, Estrela JM. Regulation of tumour cell sensitivity to TNF-induced oxidative stress and cytotoxicity: role of glutathione. Biofactors 1998;8:23-6. (Pubitemid 28332780)
32. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associatedwithmarked increase of glutathione synthesis. Proc Natl Acad Sci U S A 1992;89:3070-4.
33. Kigawa J,Minagawa Y, Kanamori Y, Itamochi H, Cheng X, Okada M, et al. Glutathione concentrationmay be a useful predictor of response to second-line chemotherapy in patients with ovarian cancer. Cancer 1998;82:697-702. (Pubitemid 28090281)